Ifebemtinib – a highly selective, orally bioavailable FAK (focal adhesion kinase) inhibitor discovered by Boehringer Ingelheim and developed by InxMed, shows significant potential as a cancer therapy.

We have created a set of analogs for this molecule!

Ifebemtinib is a promising treatment for various cancers. It is a small molecule inhibitor of FAK, demonstrating efficacy in preclinical models. In a Phase Ib/II clinical trial, ifebemtinib combined with the KRAS G12C inhibitor, garsorasib, achieved an overall response rate of 90.3% and a disease control rate of 96.8% in patients with locally advanced or metastatic solid tumors harboring the KRAS G12C mutation. The combination therapy was well tolerated, with manageable adverse events.

Explore a comprehensive selection of in-stock and make-on-demand molecules at chem-space.com tailored to your research needs. Interested or have any questions? Contact us at info@chem-space.com.